Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06083324 · ClinicalTrials.gov registry record

EXErcise Regimen Designed to Improve Functional Mobility, Body Composition, and Strength After Treatment for Cancer

A clinical trial of Cancer, sponsored by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute).

Recruiting
Registry status
100
Enrollment target
1
Study location

NCT06083324: Recruiting study of Cancer, sponsored by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute).

NCT06083324 is a study of Cancer that is actively recruiting participants, run by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute). The registered enrollment target is 100 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT06083324, a study of Cancer, is actively recruiting participants, sponsored by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute).

RECRUITING
Registry status
100 participants
Enrollment target
1
Study location

Study Summary

This protocol seeks to analyze patient outcomes of the standard of care, monitored group exercise regimen of high-load resistance training and functional exercises with compound movements under close supervision on individuals who have been treated for cancer.

Primary Outcome

Measurement on bioimpedance analysis machine (Inbody 970)

Conditions Studied

Interventions

  • OTHER Dose escalated resistance training

Study Locations (1)

Pennsylvania

  • AHN CI Exercise Oncology and Resiliency Center - Pittsburgh

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2023-02-03
Est. Completion 2026-01-26

What NCT06083324 shows while recruiting

NCT06083324 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Dose escalated resistance training is the first listed.

NCT06083324 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06083324 about?

NCT06083324 is a clinical study titled "EXErcise Regimen Designed to Improve Functional Mobility, Body Composition, and Strength After Treatment for Cancer". This protocol seeks to analyze patient outcomes of the standard of care, monitored group exercise regimen of high-load resistance training and functional exercises with compound movements under close supervision on individuals who have been treated for cancer.

What is the current status of trial NCT06083324?

This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2023-02-03. Estimated completion is 2026-01-26.

What conditions does trial NCT06083324 study?

This clinical trial studies the following conditions: Cancer.

What interventions are being tested in trial NCT06083324?

The interventions under investigation include: Dose escalated resistance training (OTHER).

Who is sponsoring clinical trial NCT06083324?

This trial is sponsored by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute), which has 34 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06083324 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06083324's enrollment target sits among peer trials

100 313th of 615 higher than 287 of 615 other Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06083324, the US trial registry maintained by the National Library of Medicine. NCT06083324 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.